Finance

Lists
4528:TYO
Ono Pharmaceutical Co Ltd
2 460,00 JPY
-1,76%
(-44,00) 1D
20 ნოე, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
2 454 JPY
High
2 508 JPY
Low
2 452 JPY
Mkt. cap
1,23 ტრლ.
Avg. vol.
1,93 მლნ.
Volume
2,30 მლნ.
Dividend
3,25%
Quarterly dividend
20 JPY
Ex-dividend date
30 მარ. 2027
P/E ratio
15,49
52-wk high
2 674 JPY
52-wk low
2 014 JPY
EPS
159 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
Open
2 454 JPY
High
2 508 JPY
Low
2 452 JPY
Mkt. cap
1,23 ტრლ.
Avg. vol.
1,93 მლნ.
Volume
2,30 მლნ.
Dividend
3,25%
Quarterly dividend
20 JPY
Ex-dividend date
30 მარ. 2027
P/E ratio
15,49
52-wk high
2 674 JPY
52-wk low
2 014 JPY
EPS
159 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
News stories
From web sources and news partners
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,21 ათ.
Founded1717
Headquartersოსაკა, Osaka, იაპონია
SectorHealth Care
IndustryPharmaceutical industry
Last report
28 ოქტ. 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
116,34 მლრ. / 116,61 მლრ.
-0,23%miss
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
139,90 მლრ.
118,75 მლრ.
116,16 მლრ.
116,34 მლრ.
Cost of goods sold
36,68 მლრდ.
33,06 მლრდ.
28,68 მლრდ.
28,75 მლრდ.
Cost of revenue
36,68 მლრდ.
33,06 მლრდ.
28,68 მლრდ.
28,75 მლრდ.
Research and development expenses
33,53 მლრდ.
42,49 მლრდ.
32,40 მლრდ.
36,69 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,73 მლრდ.
27,70 მლრდ.
23,90 მლრდ.
24,03 მლრდ.
Operating expense
67,00 მლრდ.
77,09 მლრდ.
56,83 მლრდ.
60,34 მლრდ.
Total operating expenses
103,68 მლრ.
110,15 მლრ.
85,51 მლრდ.
89,09 მლრდ.
Operating income
36,22 მლრდ.
8,60 მლრდ.
30,65 მლრდ.
27,25 მლრდ.
Other non operating income
-
318,00 მლნ.
-2,00 მლნ.
2,00 მლნ.
EBT including unusual items
37,20 მლრდ.
3,28 მლრდ.
31,25 მლრდ.
27,17 მლრდ.
EBT excluding unusual items
37,20 მლრდ.
8,77 მლრდ.
31,25 მლრდ.
27,17 მლრდ.
Income tax expense
8,31 მლრდ.
2,24 მლრდ.
7,09 მლრდ.
6,30 მლრდ.
Effective tax rate
22,35%
68,23%
22,68%
23,19%
Other operating expenses
1,73 მლრდ.
3,81 მლრდ.
526,00 მლნ.
-376,00 მლნ.
Net income
28,86 მლრდ.
818,00 მლნ.
24,15 მლრდ.
20,78 მლრდ.
Net profit margin
20,63%
0,69%
20,79%
17,86%
Earnings per share
-
-
-
-
Interest and investment income
1,39 მლრდ.
195,00 მლნ.
1,38 მლრდ.
1,12 მლრდ.
Interest expense
-408,00 მლნ.
-34,00 მლნ.
-783,00 მლნ.
-1,21 მლრდ.
Net interest expenses
979,00 მლნ.
161,00 მლნ.
598,00 მლნ.
-87,00 მლნ.
Depreciation and amortization charges
-
3,10 მლრდ.
-
-
EBITDA
45,82 მლრდ.
18,21 მლრდ.
39,63 მლრდ.
36,33 მლრდ.
Gain or loss from assets sale
-
2,20 მლრდ.
-
-
Upcoming events
AI content may include mistakes. Learn more
Google აპები